Evidence map›Paper›PMID 31951525›Full record

ArticleNeuron2020

Antidepressant Effects and Mechanisms of Group II mGlu Receptor-Specific Negative Allosteric Modulators.

Liam E Potter, Panos Zanos, Todd D Gould

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuron, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Liam E PotterDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
Panos ZanosDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA; Department of Pharmacology, University of Maryland School of Medicine, Baltimore, MD, USA; Department of Physiology, University of Maryland School of Medicine, Baltimore, MD, USA.
Todd D GouldDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA; Department of Pharmacology, University of Maryland School of Medicine, Baltimore, MD, USA; Department of Physiology, University of Maryland School of Medicine, Baltimore, MD, USA; Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, USA; Veterans Affairs Maryland Health Care System, Baltimore, MD 21201, USA. Electronic address: gouldlab@me.com.

Funding

Therapeutic Efficacy of Ketamine Metabolites for Depression TreatmentR01MH107615 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI GOULD, TODD D · 2016 to 2025
$7.2M
Targeting the inflammatory response to treat post-traumatic anxiety and depression.I01BX003631 · VA · BALTIMORE VA MEDICAL CENTER · PI GOULD, TODD D · 2017 to 2021
–
Hydroxynorketamine for the Treatment of PTSD and AnhedoniaI01BX004062 · VA · BALTIMORE VA MEDICAL CENTER · PI GOULD, TODD D · 2019 to 2023
–
BLRD VA I01 BX003631BLRD VA I01 BX004062NIMH NIH HHS R01 MH107615
6 · The paper itself

Abstract

In this issue of Neuron, Joffe et al. (2020) assess the antidepressant-relevant effects and underlying neural mechanisms of negative allosteric modulators selective for either metabotropic glutamate receptors 2 (mGlu

Indexed as

Antidepressive AgentsPyramidal CellsAnimalsMiceNeuronsPrefrontal CortexAntidepressive Agents

Identifiers

PMID31951525
PMCPMC8011990

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.